Skip to main content
Premium Trial:

Request an Annual Quote

Genomics One Reports Lower Revenues, Higher Net Loss for 2004

NEW YORK, Feb. 21 (GenomeWeb News) - Genomics One reported last week an increased net loss in 2004 amid declining revenues.

According to the Quebec-based genomics products research firm, its sales for the year were down 11.7 percent to $328,426 from 2003. Genomics One attributed the drop to the weakening US dollar, which allowed American competitors to sell their products in Canada at reduced prices. As a result, Genomics One said it had to reduce the prices on its products to remain competitive.

Costs associated with commercialization and market development rose to $635,211 in 2004 from $535,349 the year before. Meanwhile, general and administrative expenses in 2004 dropped to $878,636 from about $1 million in 2003.

Genomics One posted a net loss of $798,932 in 2004, up from a loss of $589,972 in 2003.

The company had working capital of $871,463 at the end of 2004, and said that it seeking additional financing to ensure that it has resources to fund operations beyond 2005.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.